RESEARCH ARTICLE

The association between FOXO3a rs4946936 gene polymorphism and the levels of FOXO3a among chronic granulocytic leukemia patients treated with imatinib mesylate [version 1; peer review: 2 approved with reservations]

Shinta Oktya Wardhani ¹, Hani Susianti ², Puji Rahayu³, Yuyun Prabowowati Yueniwati⁴, Jonny Karunia Fajar ⁵

¹Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

²Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

³Department of Otorhinolaryngology, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

⁴Department of Radiology, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

⁵Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

V1 First published: 04 Oct 2021, 10:1003
<https://doi.org/10.12688/f1000research.73054.1>
 Second version: 02 Mar 2022, 10:1003
<https://doi.org/10.12688/f1000research.73054.2>
 Latest published: 11 Apr 2022, 10:1003
<https://doi.org/10.12688/f1000research.73054.3>

Abstract

Background: The gene *FOXO3a* has been elucidated to govern the development of chronic granulocytic leukemia (CGL). Moreover, it has been suggested that the levels of *FOXO3a* in circulation are affected by the *FOXO3a* rs4946936 gene polymorphism. However, no study has assessed the correlation between the *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a*. The objective of this study was to assess the association between the *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a* in CGL patients treated with imatinib mesylate.

Methods: A cross-sectional study was conducted from February 2019 to February 2020. The genotyping of *FOXO3a* rs4946936 gene polymorphism was conducted using PCR-RFLP, and the levels of *FOXO3a* were assessed using ELISA. The association between the *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a* were assessed using multiple logistic regression.

Results: A total of 60 CGL patients were assessed in our study. Among them, the CC, CT, and TT genotypes of the *FOXO3a* rs4946936 gene

Open Peer Review

Approval Status

	1	2
version 3		
(revision)	view	
11 Apr 2022		
version 2		
(revision)	view	view
02 Mar 2022		
version 1		
04 Oct 2021	view	view

1. Kazuhito Naka , Hiroshima University, Hiroshima, Japan
2. Mardiah Hardianti, Universitas Gadjah Mada, Yogyakarta, Indonesia

polymorphism were 35.0%, 48.3%, and 16.7% respectively. Our calculation revealed that elevated levels of *FOXO3a* were found in CGL patients with the CC genotype of the *FOXO3a* rs4946936 gene polymorphism. While we failed to clarify the association between either the CT or the TT genotype of *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a*.

Conclusion: Our study identifies that the CC genotype of the *FOXO3a* rs4946936 gene polymorphism affects the elevated levels of *FOXO3a* in CGL patients treated with imatinib mesylate.

Keywords

chronic granulocytic leukemia, *FOXO3a*, *FOXO3a* rs4946936 gene polymorphism

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the **Oncology** gateway.

Corresponding authors: Shinta Oktya Wardhani (shinta_oktya.fk@ub.ac.id), Jonny Karunia Fajar (gembyok@gmail.com)

Author roles: **Wardhani SO:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation; **Susianti H:** Conceptualization, Supervision; **Rahayu P:** Conceptualization, Investigation, Methodology, Supervision, Validation; **Yueniwati YP:** Conceptualization, Investigation, Methodology, Supervision, Validation, Visualization, Writing – Review & Editing; **Fajar JK:** Methodology, Software, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Wardhani SO *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Wardhani SO, Susianti H, Rahayu P *et al.* **The association between *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a* among chronic granulocytic leukemia patients treated with imatinib mesylate [version 1; peer review: 2 approved with reservations]** F1000Research 2021, 10:1003 <https://doi.org/10.12688/f1000research.73054.1>

First published: 04 Oct 2021, 10:1003 <https://doi.org/10.12688/f1000research.73054.1>

Introduction

Chronic granulocytic leukemia (CGL), first recognized in 1845, is a myeloproliferative disease caused by a condition in which a single pluripotential haemopoietic stem cell acquires the Philadelphia chromosome.¹ A global report in 2015 revealed that the incidence of this disease was estimated between 0.7 and 1.0 per 100,000 inhabitants,² while mortality was reported at less than 15%.³ The pathogenesis of CGL is a comprehensive process, and may involve a wide variety of biomarkers including cyclooxygenase 1 (*COX1*), patched homolog 1 (*PTCH1*), Forkhead Transcription Factor 3a (*FOXO3a*), prostaglandin-endoperoxide synthase 1 (*PTGS1*), and human organic cation transporter 1 (*hOCT1*).^{4–6} Of them, *FOXO3a* is proposed as one biomarker having a pertinent role in the pathogenesis of CGL, although evidence is limited.⁶

FOXO3a belongs to the FOXO Forkhead transcription factors subfamily. The subfamily of FOXO includes *FOXO1*, *FOXO3a*, *FOXO3b*, *FOXO4* and *FOXO6*.⁷ Of them, *FOXO3a* plays a dominant role in carcinogenesis including cell cycle progression, proliferation, the activation of reactive oxygen species, DNA damage, apoptosis, and tumorigenesis.⁸ Moreover, the existence of *FOXO3a* in the circulation is governed by the *FOXO3a* gene, which has several single nucleotide polymorphisms (SNPs) such as rs2802292, rs2764264, rs4945816, rs9400239, rs4946936, and rs13217795.⁹ Of them, the *FOXO3a* rs4946936 gene variant is suggested to have a crucial role in affecting the levels of *FOXO3a* in circulation, and therefore may have a potential role in the pathogenesis of CGL. While the gene polymorphism of *FOXO3a* rs4946936 has been investigated in the case of vitiligo,¹⁰ chronic obstructive pulmonary disease (COPD),¹¹ acute lymphoblastic leukemia,¹² thyroid cancer,¹³ and hepatocellular carcinoma,¹⁴ the role of *FOXO3a* rs4946936 gene polymorphisms in the development of CGL has never been examined. Therefore, we aimed to assess the correlation between *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a* in patients with CGL treated with imatinib mesylate. Our report may serve as an initial insight into the role of the *FOXO3a* rs4946936 gene polymorphism in the pathogenesis of CGL.

Methods

Study design and patients

During the period from February 2019 to February 2020, we conducted a cross-sectional study in Saiful Anwar General Hospital, Malang, Indonesia. A total sampling method was applied to recruit the study participants (a total of 26 participants was needed as the minimum sample size according to the estimation that the prevalence of CGL was 10–12 per 100,000 inhabitants with a 5% margin of error and 95% confidence level). The patients were included in our study if they met the following inclusion criteria: (1) all CGL patients (confirmed by a positive Bcr-ABL test) treated with imatinib mesylate for at least six months in our hospital during the study period, (2) aged more than 18 years old, and (3) willing to participate in the study, proven by giving written informed consent. Patients were excluded from our study if they had a history of the following conditions: prostate cancer, gynecological cancer, COPD, breast cancer, vitiligo, and thyroid cancer.¹⁵ Our present study was conducted following the ethics code of the Helsinki Declaration and was registered and approved by the Ethical Committee of Universitas Brawijaya (No. 400/098/k.3/302/2019).

Genotyping of *FOXO3a* rs4946936 gene polymorphism

We collected venous blood in plastic vacutainer tubes containing EDTA. We separated the blood samples, and they were stored at -20°C . We centrifuged the blood samples in EDTA at $1000 \times g$ for 10 min, and we separated the plasma and stored it at -20°C until it was used to measure *FOXO3a* levels. A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was applied to genotype the *FOXO3a* rs4946936 gene polymorphism. The procedures in *FOXO3a* genotyping including the primer used, amplification, and PCR cycles (initial denaturation, denaturation, annealing, and extension) were adapted from previous studies,^{10,11} using the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, California, USA). The *FOXO3a* primer (*FOXO3a* F: 5'-GGGTCCTGAGAACTTCTGAGT-3'; *FOXO3a* R: 5'-GACATTCTGTAAGACATTCTGCCT-3') used in our present study was MyTaq HS Mix, 2X (Bioline, Meridian Bioscience™, OH, USA). We used SfcI (New England Biolabs, Massachusetts, USA) as the restriction enzyme. PCR was conducted in a 50 μl volume with 20–100 ng DNA, 20 pmol of each primer, 50 μM KCl, 100 μM dNTPs, 20 μM Tris-HCl pH 8.6,

1 mM MgCl_2 , and 1 U Taq polymerase (MBI Fermentas, Vilnius, Lithuania). Amplification was carried out using an automated thermal cycler (Techne-Genius, Princeton, NJ). The PCR cycles consisted of initial denaturation at 94°C for 3 min; 35 cycles of denaturation at 94°C for 1 min, annealing at 53°C for 1 min, and extension at 72°C for 1 min, followed by final extension at 72°C for 7 min. The amplified products were digested with one unit of SfcI (rs4946936; C/T). The digested fragments were separated on 2% agarose gel by electrophoresis. The genotypes were identified according to their fragment sizes. The TT genotype was characterized by 224 bp sized bands, the TC genotype was characterized by 224, 152, and 72 bp sized bands, and the size bands of 152 and 72 indicated the CC genotype (Figure 1).

Figure 1. A visualization of the *FOXO3a* rs4946936 gene polymorphism. The 224bp sized band indicated TT genotype, the 152bp size band indicated CT genotype, and the 72bp sized band indicated CC genotype.

The measurement of *FOXO3a* levels

The measurement of serum *FOXO3a* levels was conducted by the enzyme-linked immunosorbent assay (ELISA) method, using the Cusabio kit (Cusabio Biotech Co., New York, USA), with the procedures conforming to the manual instructions from the company. The 100 μ l standard liquid and blood sample were added to the tubes, and incubated for 90 min. The liquid from each tube was then shaken. The 100 μ l biotinylated detection antibody was added to each tube and incubated at 37 °C for 1h. The liquid of each tube was shaken and washed three times. The 100 μ l 1x HRP conjugate was then added to each tube and incubated at 37 °C for 30 min. The liquid was shaken and washed five times. The 90 μ l TMB substrate was added to each tube and incubated at 37 °C for 15 min. The 50 μ l stopper liquid was added to each tube. At this step, a change from blue to yellow might occur. Measurement of optic density at 450 nm was conducted. The results were then interpreted to the standard curve to determine the levels of *FOXO3a* and expressed in units of pg/mL.

Statistical analysis

The correlation between the *FOXO3a* rs4946936 gene polymorphism and *FOXO3a* levels was assessed using multiple logistic regression. A p-value of less than 0.05 indicated a significant association. The effect estimates between groups were presented by calculation of the mean difference. We used the R stats package statistical software to analyze the data in our study (R Project for Statistical Computing, RRID:SCR_001905).

Results

Baseline characteristics

A total of 60 CGL patients were analyzed. Of them, 21 (35.0%), 29 (48.3%), and 10 (16.7%) patients had a CC, CT, and TT genotype, respectively. Initially, we employed a total of 68 CGL patients, however, eight patients were excluded due to having a history of gynecological cancer and COPD. Table 1 describes the baseline characteristics of patients included in our study. The detailed data are presented as underlying data.¹⁶

Main findings

Our findings identified that elevated levels of *FOXO3a* were observed among CGL patients with CC (CC vs. CT + TT) genotype (MD: 26.56; 95% CI: 0.48, 52.64). While the association between the CT (CT vs. CC + TT) and TT (TT vs. CC + CT) genotypes and the levels of *FOXO3a* were unverified (Table 2).

Discussion

Our study identified that the CC genotype of the *FOXO3a* rs4946936 gene polymorphism was associated with increased levels of *FOXO3a* among patients with CGL treated with imatinib mesylate. The study in the context of the association between the *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a* in patients with CGL treated with imatinib mesylate had, to our knowledge, never been performed previously, therefore, an holistic comparison including the gene-ethnicity or gene-environment interaction could not be discussed. Previous studies in this context had been performed in the case of COPD¹¹ and vitiligo.¹⁰ In the case of vitiligo, a study failed to clarify the correlation between the levels of *FOXO3a* and the gene polymorphism of *FOXO3a* rs4946936.¹⁰ Moreover, in the case of COPD, no association was observed between the levels of *FOXO3a* and the gene polymorphism of *FOXO3a* rs4946936.¹¹ The different findings between our study in the case of CGL and previous studies in the case of vitiligo and COPD are contradictory and

Table 1. Baseline characteristics of chronic granulocytic leukemia patients treated with imatinib mesylate included in the study examining the association between *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a*.

Characteristics	<i>FOXO3a</i> gene polymorphism			p
	CC	CT	Total	
Gender				
Male	11 (18.30)	15 (25.00)	26 (43.30)	0.992
Female	10 (16.70)	14 (23.30)	24 (40.00)	
Age	43.62 ± 11.75	41.9 ± 12.53	42.76 ± 12.14	0.877
Spleen				
S3	4 (6.70)	4 (6.70)	8 (13.30)	0.455
S4	6 (10.00)	7 (11.70)	13 (21.70)	
S5	5 (8.30)	13 (21.70)	18 (30.00)	
S6	6 (10.00)	5 (8.30)	11 (18.30)	
Hemoglobin	11.59 ± 4.18	10.9 ± 3	11.24 ± 3.59	0.559
Leucocyte	25698.1 ± 56533.51	42165.55 ± 94168.6	33931.83 ± 65351.08	0.013
Thrombocyte	218047.62 ± 102640.38	423241.38 ± 963616.32	320644.50 ± 129488.85	0.575

Note: Total no. of patients = 60. Data were presented as mean ± SD or no. (%).

Table 2. The summary of *FOXO3a* levels and the gene polymorphism of *FOXO3a* in chronic granulocytic leukemia patients treated with imatinib mesylate.

<i>FOXO3a</i> gene polymorphism	The levels of <i>FOXO3a</i> between groups						p
	Mean	SD	N	Mean	SD	N	
CC vs. CT+TT	77.34	47.65	21	50.78	49.94	39	0.0460
CT vs. CC+TT	55.71	50.87	29	64.16	50.43	31	0.5180
TT vs. CC+CT	36.47	46.64	10	64.8	50.21	50	0.1000

Note: Data were presented as mean ± SD; MD = mean difference.

debatable, and a possible reason might be proposed. Briefly, vitiligo and COPD are known as conditions that affect the levels of *FOXO3a*, and the mechanism of *FOXO3a* production in the case of CGL might differ to the case of vitiligo and COPD. In the case of vitiligo, *FOXO3a* may interrupt the oxidative pathway by controlling the target gene expression.¹⁰ In the case of COPD, *FOXO3a* may stimulate the expression of Atrogin-1/MAFbx, a biological marker having a pivotal role in the development of COPD.¹¹ On the other hand, the role of *FOXO3a* in the case of CGL occurs through establishing the phosphorylation by p210BCR-ABL tyrosine kinase, and may contribute to the proliferation of leukemic progenitors.^{17,18}

Theoretically, the association between the levels of *FOXO3a* and the gene polymorphism of *FOXO3a* rs4946936 remain conflicting. However, several mechanisms might be proposed. First, the gene-gene interaction or gene-protein interaction might underly our findings. This possible mechanism was supported by a previous study.¹⁹ The authors revealed that a dominant homozygote genotype of the *FOXO3a* rs4946936 gene variant was reported to associate with elevated levels of immunoglobulin (Ig) E in the case of asthma. They proposed that *FOXO3a* might regulate the production of proinflammatory cytokine, and cause elevated levels of IgE.¹⁹ Second, free energy levels between genotypes of the *FOXO3a* rs4946936 gene polymorphism might affect the levels of *FOXO3a* in the circulation. In an *in silico* study, the free energy levels of the CC and TT genotype of the *FOXO3a* rs4946936 gene variant were -320.80 Kcal/mol and -301.10 Kcal/mol, respectively, indicating that the CC genotype had lower free energy levels.²⁰ Low free energy levels were associated with the mRNA structure and translation, and the changes of mRNA translation at the 5' and 3' UTR locations were correlated to affect protein synthesis.^{20–22} This explanation might describe the possible underlying mechanism that the CC genotype of the *FOXO3a* rs4946936 gene variant had an association with increased levels of *FOXO3a* in the case of CGL compared to the CT and TT genotype.

To the best of our knowledge, our study is the first to report the association between the levels of *FOXO3a* and the gene polymorphism of *FOXO3a* rs4946936 in the case of CGL patients. Our findings may serve as an initial investigation regarding the role of *FOXO3a* rs4946936 gene polymorphism in affecting the levels of *FOXO3a*, compared to different findings in the case of COPD and vitiligo. In the future, our results may contribute to a better understanding regarding the role of *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a* in the pathogenesis of CGL patients. However, understanding the role of genetics in a disease is problematic and further studies involving gene-gene, gene-environment, and gene-disease interaction are warranted to determine the holistic role of *FOXO3a* gene polymorphism in the pathogenesis of CGL.

Several pertinent limitations to this study should be assessed. First, several factors that might contribute to the severity of CGL in patients including smoking, physical activity, dietary factors, the history of previous medication, and the history of radiation were not analyzed. Second, the small sample size in our study should be interpreted with caution due to the possibility of false positive results. Third, the short time period of the study might not be sufficient to define the real correlation.

Conclusion

Our study indicates that the CC genotype of the *FOXO3a* rs4946936 gene variant is associated with elevated levels of *FOXO3a*. Our findings may be used as an initial investigation and may provide a better understanding of the role of the *FOXO3a* rs4946936 gene variant in the pathogenesis of CGL.

Data availability

Underlying data

Figshare: Underlying data for 'The association between *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a* among chronic granulocytic leukemia patients treated with imatinib mesylate', <https://doi.org/10.6084/m9.figshare.16529160>.¹⁶

This project contains the following underlying data:

- Data file.xlsx
- Gel electrophoresis.pdf

Reporting guidelines

Figshare: STROBE checklist for 'The association between *FOXO3a* rs4946936 gene polymorphism and the levels of *FOXO3a* among chronic granulocytic leukemia patients treated with imatinib mesylate', <https://doi.org/10.6084/m9.figshare.16529160>.¹⁶

Data are available under the terms of the [Creative Commons Attribution 4.0 International license \(CC-BY 4.0\)](#)

Consent

Written informed consent for publication of the patients' details was obtained from the patients.

Acknowledgements

We thank RSUD Dr Saiful Anwar Malang for supporting our study.

References

1. Frazer R, Irvine AE, McMullin MF: **Chronic Myeloid Leukaemia in The 21st Century.** *Ulster Med J.* 2007; **76**: 8–17.
[PubMed Abstract](#) | [Free Full Text](#)
2. Hoglund M, Sandin F, Simonsson B: **Epidemiology of chronic myeloid leukaemia: an update.** *Ann Hematol.* 2015; **94**(Suppl 2): 241–247.
[Publisher Full Text](#)
3. Granatowicz A, Piatek CI, Moschiano E, *et al.*: **An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians.** *Korean J Fam Med.* 2015; **36**: 197–202.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Clark RE, Davies A, Pirmohamed M, *et al.*: **Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia.** *Leuk Lymphoma.* 2008; **49**: 639–642.
[Publisher Full Text](#) | [PubMed Abstract](#)
5. Alonso-Dominguez JM, Casado LF, Anguita E, *et al.*: **PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.** *PLoS One.* 2017; **12**: e0181366.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Stefanetti RJ, Voisin S, Russell A, *et al.*: **Recent advances in understanding the role of FOXO3.** *F1000Res.* 2018; **7**: 7.
[Publisher Full Text](#)
7. Schmitt-Ney M: **The FOXO's Advantages of Being a Family: Considerations on Function and Evolution.** *Cells.* 2020; **9**:
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Liu Y, Ao X, Ding W, *et al.*: **Critical role of FOXO3a in carcinogenesis.** *Mol Cancer.* 2018; **17**: 104.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Daumer C, Flachsbart F, Caliebe A, *et al.*: **Adjustment for smoking does not alter the FOXO3A association with longevity.** *Age (Dordr).* 2014; **36**: 911–921.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Ozel Turkcu U, Solak Tekin N, Gokdogan Edgunlu T, *et al.*: **The association of FOXO3A gene polymorphisms with serum FOXO3A levels and oxidative stress markers in vitiligo patients.** *Gene.* 2014; **536**: 129–134.
[Publisher Full Text](#) | [PubMed Abstract](#)
11. Kalemci S, Edgunlu TG, Turkcu U, *et al.*: **FOXO3a gene polymorphism and serum FOXO3a levels in patients with chronic obstructive pulmonary disease and healthy controls: Effects of genetic polymorphism in chronic obstructive pulmonary disease.** *Smyrna Med J.* 2014; **1**: 1–5.
[PubMed Abstract](#)
12. Wang Y, Zhou L, Chen J, *et al.*: **Association of the 3'UTR FOXO3a polymorphism rs4946936 with an increased risk of childhood acute lymphoblastic leukemia in a Chinese population.** *Cell Physiol Biochem.* 2014; **34**: 325–332.
[Publisher Full Text](#) | [PubMed Abstract](#)
13. Roehlen N, Doering C, Hansmann ML, *et al.*: **Vitamin D, FOXO3a, and Sirtuin1 in Hashimoto's Thyroiditis and Differentiated Thyroid Cancer.** *Front Endocrinol (Lausanne).* 2018; **9**: 527.
[Publisher Full Text](#)
14. Tan C, Liu S, Tan S, *et al.*: **Polymorphisms in microRNA target sites of forkhead box O genes are associated with hepatocellular carcinoma.** *PLoS One.* 2015; **10**: e0119210.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Wardhani SO, Susanti H, Rahayu P, *et al.*: **The Levels of FoxO3a Predict the Failure of Imatinib Mesylate Therapy among Chronic Myeloid Leukemia Patients.** *Open Access Macedonian J Med Sci.* 2021; **9**: 255–259.
[Publisher Full Text](#)
16. Shinta OW, Susianti H, Rahayu P, *et al.*: **Underlying data for 'The association between FOXO3a rs4946936 gene polymorphism and the levels of FOXO3a among chronic granulocytic leukemia patients treated with imatinib mesylate.** *Figshare.* 2021.
[Publisher Full Text](#)
17. Li L: **The Role of MicroRNAs in Vitiligo: Regulators and Therapeutic Targets.** *Ann Dermatol.* 2020; **32**: 441–451.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Hwang JW, Rajendrasozhan S, Yao H, *et al.*: **FOXO3 deficiency leads to increased susceptibility to cigarette smoke-induced inflammation, airspace enlargement, and chronic obstructive pulmonary disease.** *J Immunol.* 2011; **187**: 987–998.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Imraish A, Abu-Thiab T, Zihlif M: **IL-13 and FOXO3 genes polymorphisms regulate IgE levels in asthmatic patients.** *Biomed Rep.* 2021; **14**: 55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Uddin SN, Majumder A, Islam KK, *et al.*: **Minimum free energy based evaluation of mRNAs secondary structures constructed by 18 clinically significant exonic single nucleotide polymorphisms (SNPs) and haplotypes of 5 missense SNPs of RB1 gene.** *Am J Biochemistry Biotechnol.* 2015; **11**: 191–199.
[Publisher Full Text](#)
21. Salari R, Kimchi-Sarfaty C, Gottesman MM, *et al.*: **Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies.** *Nucleic Acids Res.* 2013; **41**: 44–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Sionov RV, Vlahopoulos SA, Granot Z: **Regulation of Bim in Health and Disease.** *Oncotarget.* 2015; **6**: 23058–23134.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status: ? ?

Version 1

Reviewer Report 10 February 2022

<https://doi.org/10.5256/f1000research.76675.r120814>

© 2022 Hardianti M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mardiah Hardianti

Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Dr. Sardjito Hospital, Universitas Gadjah Mada, Yogyakarta, Indonesia

1. The idea of this paper is original and highly appreciated. It aimed to elucidate one of the important molecular mechanism of CGL by assessing the target gene polymorphism and its protein FOXO3a. The finding that CC genotype was related to the higher level of FOXO3a which might be related with disease mechanism was explained well by referring to other disease mechanism such as vitiligo and COPD. However, it is still suggested to be explained more in the aspect of molecular mechanism of hematological malignancy.
2. Other possible explanations for the uninvolved role of CT or TT polymorphisms in CGL disease mechanism should be explained more rather than just comparing their biochemical aspect to the CC phenotype which stated that CC phenotype produced higher level of FOXO3a protein. Any technical or sampling issues could also be other explanations for this finding.
3. Is there any possible extrapolation for disease mechanism from Indonesian population regarding CC phenotype findings in this study? Please explain either when the answer is yes or no.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Molecular mechanism of cancer

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 27 Feb 2022

Jonny Fajar

Reviewer2

1. The idea of this paper is original and highly appreciated. It aimed to elucidate one of the important molecular mechanism of CGL by assessing the target gene polymorphism and its protein FOXO3a. The finding that CC genotype was related to the higher level of FOXO3a which might be related with disease mechanism was explained well by referring to other disease mechanism such as vitiligo and COPD. However, it is still suggested to be explained more in the aspect of molecular mechanism of hematological malignancy.

Response: The additional explanation on the possible role of FOXO3a in the context of hematological malignancy has been provided.

2. Other possible explanations for the uninvolved role of CT or TT polymorphisms in CGL disease mechanism should be explained more rather than just comparing their biochemical aspect to the CC phenotype which stated that CC phenotype produced higher level of FOXO3a protein. Any technical or sampling issues could also be other explanations for this finding.

Response: The explanation regarding the possible reason why CC genotype may associate with the higher production of FOXO3a levels compared to CT and TT genotypes has been provided in the discussion paragraph 2 (the possible association between the genotype and free energy levels).

3. Is there any possible extrapolation for disease mechanism from Indonesian population regarding CC phenotype findings in this study? Please explain either when the answer is yes or no.

Response: The additional explanation on the possible gene – environment interaction including Indonesian population has been provided.

Competing Interests: We have no competing interest to declare.

Reviewer Report 13 January 2022

<https://doi.org/10.5256/f1000research.76675.r118690>

© 2022 Naka K. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kazuhito Naka

Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

In the valuable manuscript, the authors investigated association between FOXO3a polymorphism and the levels of FOXO3a in serum from chronic granulocytic leukemia (CGL) patients after treatment with imatinib mesylate. They indicated that the CC, CT, and TT genotypes of the FOXO3a rs4946936 gene polymorphism were 35.0%, 48.3%, and 16.7%, respectively. Interestingly, the levels of FOXO3a were elevated in the CGL patients with CC genotype of the FOXO3a rs4946936 gene than those with the CT and TT genotypes. Collectively, the authors concluded that the CC genotype of the FOXO3a rs4946936 gene polymorphism affects the elevated levels the FOXO3a in CGL patients treated with imatinib mesylate.

Major points

In table 2, it is difficult to understand what it means, while it indicates important findings in this study. Probably, first “Mean” reveals the expression levels of FOXO3a. But, I cannot understand the second “Mean”. Please explain each “Mean”. I strongly recommend that the authors reveal the data as “bar graphs” rather than table. It helps the understanding of a wide variety of readers.

I understood the authors' findings that the CC genotype of the FOXO3a rs4946936 gene polymorphism appears to be correlated with the expression of FOXO3a in the serum of CGL patients treated with imatinib mesylate. However, the authors should indicate clinical significance of the genotype. For example, they should compare the therapeutic effects of imatinib mesylate between the CC genotype and CT and TT genotypes, such as IS of BCR-ABL1 or deep molecular response (DMR) patients. They should also indicate whether or not the levels of FOXO3a in the CC genotypes are elevated post-imatinib administration than pre-imatinib therapy. These data may contribute to predict the therapeutic effect of imatinib mesylate in the patients.

Minor point

In the introduction, the authors described that "FOXO3a plays a dominant role in carcinogenesis including cell cycle progression, proliferation, the activation of reactive oxygen species, DNA damage, apoptosis, and tumorigenesis." However, it has been known that FOXO3a is implicated in "cell cycle arrest", "detoxification of reactive oxygen species", and "DNA damage repair". Thus, please correct the descriptions.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

No source data required

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Tyrosine kinase inhibitor (TKI) resistant relapse of chronic myelogenous leukaemia (CML) patients.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 27 Feb 2022

Jonny Fajar

Reviewer1

1. In table 2, it is difficult to understand what it means, while it indicates important findings in this study. Probably, first "Mean" reveals the expression levels of FOXO3a. But, I cannot understand the second "Mean". Please explain each "Mean". I strongly recommend that the authors reveal the data as "bar graphs" rather than table. It helps the understanding of a wide variety of readers.

Response: We have provided Figure 2 instead of Table 2, as suggested by reviewer.

2. I understood the authors' findings that the CC genotype of the FOXO3a rs4946936 gene polymorphism appears to be correlated with the expression of FOXO3a in the serum of CGL patients treated with imatinib mesylate. However, the authors should indicate clinical significance of the genotype. For example, they should compare the therapeutic effects of imatinib mesylate between the CC genotype and CT and TT genotypes, such as IS of BCR-ABL1 or deep molecular response (DMR) patients. They should also indicate whether or not the levels of FOXO3a in the CC genotypes are elevated post-imatinib administration than pre-imatinib therapy. These data may contribute to predict the therapeutic effect of imatinib mesylate in the patients.

Response: In our present study, we did not compare the levels of FOXO3 between pre and post imatinib treatment. Therefore, we could not provide the holistic information regarding those comparison. However, we have added the additional discussion about the proposed effect of FOXO3a levels and the treatment of imatinib.

3. In the introduction, the authors described that "FOXO3a plays a dominant role in carcinogenesis including cell cycle progression, proliferation, the activation of reactive oxygen species, DNA damage, apoptosis, and tumorigenesis." However, it has been known that FOXO3a is implicated in "cell cycle arrest", "detoxification of reactive oxygen species", and "DNA damage repair". Thus, please correct the descriptions.

Response: The above description has been revised.

Competing Interests: We have no competing interest to declare.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research